Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Healthcare Biotechnology
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Bullboard (TSXV:ARCH)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by Viking2233on Jan 08, 2025 9:39am

Ontario Sites

So management news releases they have ethics approval at two Ontario sites but require additional internal approvals before dosing starts. I am not sure how to react. I guess it provides additional ...more  
182
Post by Viking2233on Dec 30, 2024 1:40pm

2025

So in a few days we will enter 2025. What will this New Year bring to Arch shareholders? I hope that management decides to bring transparency and communication to the markets, communication as ...more  
246
Comment by Viking2233on Dec 09, 2024 1:18pm

RE:PONTIAC Cilastatin market update?

Welll I doubt that date is achievable and quite frankly this trial is not controlled by Arch. I think Arch's current AKi trial that involves three Canadian sites should serve as a guideline and ...more  
245
Discussion
Post by Cb27743on Dec 09, 2024 12:48pm

PONTIAC Cilastatin market update?

The PONTIAC clinical team sponsoring the trial is based in Calgary and is currently preparing to submit a Clinical Trial Application (CTA) to Health Canada to proceed with the trial by the fourth ...more  
109
Discussion
Post by Viking2233on Dec 04, 2024 12:10pm

My Concerns…..

Well another week has passed and more patients dosed but I do have concerns, not with the science, not with the drug, not with trials but with the lack of communication and the hoops a company has to ...more  
264
Post by Viking2233on Nov 24, 2024 3:41pm

Silence Continues ………

    But so does the nefarious shorting algorithms!    In my humble opinion the lack of communication and updates, just plays into the hands of those shorting.   I ...more  
298
Post by Viking2233on Nov 17, 2024 5:28pm

Nothing but Silence

Arch update   Well I wish I had something positive to report. I only have my observations and opinions.   We are 9 months into dosing in Turkey at 5 sites. Arch management reluctant ...more  
268
Comment by Viking2233on Oct 31, 2024 9:23pm

RE:Top 10 Undervalued Healthcare Sector Stocks

Thanks for this River, I have been saying this for months. We are ready to launch, glad I am not yhe only one who can see this!
162
Discussion
Post by Viking2233on Oct 29, 2024 3:18pm

Connecting the dots

1. Been dosing at 5 Turkish sites for 9 months now. Silence from management but no news in this case could be great news as no adverse reactions reported.   2. How many patients dosed? Nobody ...more  
170
Post by Viking2233on Oct 27, 2024 7:57pm

Stockholm Conference

Some interesting facts for consideration. The Stockholm conference runs from November 4 to 13. This is a 9 day conference that we are presenting at. I wonder who we are sending and how many days will ...more  
214
Post by Viking2233on Oct 23, 2024 12:11pm

California Conference

Well today marks conference number 1 that Arch is attending. I errored in my previous post stating they were presenting, in fact they are simply attending but hopefully networking aggressively. That ...more  
221
Post by Viking2233on Oct 17, 2024 6:33am

Is the end of trial near…..

Arch manangement announced on X yesterday that it will be presenting at 2 conferences starting Oct 23 in San Diego California and in November in Stockholm Sweden. Now one thing we know is Arch CEO is ...more  
384
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities